We are live on ! Find out more
TEVA icon

Teva Pharmaceuticals
TEVA

744 hedge funds and large institutions have $16.6B invested in Teva Pharmaceuticals in 2013 Q2 according to their latest regulatory filings, with 744 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

44.92% more ownership

Funds ownership: 0% → 44.92% (+45%)

11% more call options, than puts

Call options by funds: $268M | Put options by funds: $242M

Holders
744
Holders Change
+744
Holders Change %
–
% of All Funds
24.28%
Holding in Top 10
32
Holding in Top 10 Change
+32
Holding in Top 10 Change %
% of All Funds
1.04%
New
744
Increased
–
Reduced
–
Closed
–
Calls
$268M
Puts
$242M
Net Calls
+$25.9M
Net Calls Change
+$25.9M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$2.4B +$2.38B +61,239,818 New
Capital Research Global Investors
2
Capital Research Global Investors
California
$2.28B +$2.27B +58,182,900 New
MIP
3
Mondrian Investment Partners
United Kingdom
$834M +$829M +21,278,495 New
Franklin Resources
4
Franklin Resources
California
$712M +$707M +18,158,231 New
Allianz Asset Management
5
Allianz Asset Management
Germany
$574M +$570M +14,636,972 New
Invesco
6
Invesco
Georgia
$476M +$473M +12,153,843 New
Norges Bank
7
Norges Bank
Norway
$328M +$326M +8,372,291 New
Macquarie Group
8
Macquarie Group
Australia
$301M +$299M +7,684,446 New
NIMC
9
NWQ Investment Management Company
California
$266M +$264M +6,778,539 New
Barrow, Hanley, Mewhinney & Strauss
10
Barrow, Hanley, Mewhinney & Strauss
Texas
$264M +$262M +6,723,966 New
Bank of New York Mellon
11
Bank of New York Mellon
New York
$208M +$207M +5,314,122 New
U
12
UBS
Switzerland
$204M +$203M +5,204,366 New
WRF
13
Waddell & Reed Financial
Kansas
$181M +$180M +4,628,540 New
Nordea Investment Management
14
Nordea Investment Management
Sweden
$168M +$167M +4,287,768 New
MAA
15
Managed Account Advisors
New Jersey
$165M +$164M +4,219,259 New
Wells Fargo
16
Wells Fargo
California
$151M +$150M +3,845,023 New
JP Morgan Chase
17
JP Morgan Chase
New York
$149M +$148M +3,812,593 New
PIM
18
Perkins Investment Management
Illinois
$149M +$148M +3,801,829 New
Lazard Asset Management
19
Lazard Asset Management
New York
$149M +$148M +3,795,137 New
RFC
20
Russell Frank Company
Washington
$145M +$144M +3,689,604 New
TGI
21
Tradewinds Global Investors
California
$140M +$139M +3,578,874 New
ClearBridge Investments
22
ClearBridge Investments
New York
$140M +$139M +3,577,521 New
IGIM
23
I.G. Investment Management
Manitoba, Canada
$138M +$137M +3,520,254 New
SCM
24
Scopia Capital Management
New York
$137M +$136M +3,503,860 New
Capital World Investors
25
Capital World Investors
California
$134M +$134M +3,430,000 New
1
2 3 4 5

TEVA Hedge Fund Activity: Q2 2013 in Review

744 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q2 2013, worth a combined $16.6B.

Buyers outnumbered sellers: 744 funds opened new TEVA positions and 0 closed out — a net gain of 744 holders — while 0 added to existing stakes and 0 trimmed.

  • 744 institutional investors held Teva Pharmaceuticals (TEVA) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $16.6B of Teva Pharmaceuticals stock for Q2 2013.
  • 744 funds opened new Teva Pharmaceuticals positions in Q2 2013 and 0 closed out, a net change of +744 holders.

Based on aggregated 13F filings for Q2 2013.